| Title: | The endocannabinoid system in neuropsychiatric disorders : mechanisms, dysregulation and therapeutic potential |
|---|
| Authors: | ID Mušić, Timur (Author)
ID Lah Turnšek, Tamara (Author) |
|---|
| Files: |  URL - Source URL, visit https://doi.org/10.3390/biomedicines14050968
 PDF - Presentation file, download (7,03 MB)
MD5: 4A8A4C770746EB41DD23580E5A029B30
|
|---|
| Language: | English |
|---|
| Typology: | 1.02 - Review Article |
|---|
| Organization: |  NIB - National Institute of Biology
|
|---|
| Abstract: | The endocannabinoid system (ECS) is a fundamental regulator of brain and body homeostasis, integrating neural, immune, and stress-related signaling pathways. Dysregulation of ECS components, including cannabinoid receptors (CB1 and CB2), endocannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes (FAAH and MAGL), has been increasingly implicated in the pathophysiology of neuropsychiatric disorders, including mood, anxiety, psychotic, stress-related, and eating disorders. Altered endocannabinoid signaling contributes to maladaptive stress responses, emotional dysregulation, and impaired synaptic plasticity, highlighting the role of the ECS as a core integrative mechanism. Therapeutic strategies targeting ECS, particularly through FAAH inhibition and the use of plant-derived cannabinoids, such as cannabidiol (CBD), show promise in restoring endogenous homeostasis while minimizing the adverse cognitive and affective effects associated with direct CB1 activation. ECS function and treatment response are further influenced by genetic polymorphisms in CNR1, CNR2, FAAH, and MGLL, as well as epigenetic mechanisms, including DNA methylation, histone modifications, and microRNA regulation. Despite these advances, clinical translation remains limited by interindividual variability, the complexity of ECS interactions, and the relatively small size of existing clinical studies. Future research integrating longitudinal clinical trials with multi-omics approaches is essential to support the development of evidence-based, personalized interventions. Overall, understanding ECS mechanisms and dysregulation provides a valuable framework for the development of targeted therapies in neuropsychiatric disorders. |
|---|
| Keywords: | endocannabinoid system, cannabinoid receptors, anandamide, 2-arachidonoylglycerol, neuropsychiatric disorders, stress-related response, mood disorders, eating disorders, ECS gene polymorphism, ECS epigenetic modulation |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.05.2026 |
|---|
| Year of publishing: | 2026 |
|---|
| Number of pages: | str. [1]-27 |
|---|
| Numbering: | iss. 5, art. 968 |
|---|
| PID: | 20.500.12556/DiRROS-30930  |
|---|
| UDC: | 577.2 |
|---|
| ISSN on article: | 2227-9059 |
|---|
| DOI: | 10.3390/biomedicines14050968 |
|---|
| COBISS.SI-ID: | 282737923 |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 24. 6. 2026;
|
|---|
| Publication date in DiRROS: | 08.07.2026 |
|---|
| Views: | 28 |
|---|
| Downloads: | 15 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
